Jane Street Group, LLC Cel Sci Corp Transaction History

Jane Street Group, LLC

$445 Billion
Q3 2024

A detailed history of Jane Street Group, LLC transactions in Cel Sci Corp stock. As of the latest transaction made, Jane Street Group, LLC holds 10,465 shares of CVM stock, worth $6,279. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,465

Holding current value

$6,279

% of portfolio

0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.05 - $1.5 $10,988 - $15,697	10,465 New	10,465 $11,000
Q1 2024 May 15, 2024	SELL	$1.63 - $3.08 $2,197 - $4,151	-1,348 Reduced 2.24%	58,879 $112,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $3.07 $64,442 - $184,896	60,227 New	60,227 $163,000
Q4 2022 Feb 14, 2023	BUY	$1.99 - $3.52 $62,068 - $109,788	31,190 New	31,190 $73,000
Q2 2022 Aug 16, 2022	SELL	$2.58 - $4.99 $88,989 - $172,115	-34,492 Closed	0 $0
Q1 2022 May 17, 2022	SELL	$3.93 - $7.7 $489,556 - $959,181	-124,569 Reduced 78.32%	34,492 $136,000
Q4 2021 Feb 15, 2022	SELL	$7.1 - $12.82 $116,667 - $210,658	-16,432 Reduced 9.36%	159,061 $1.13 Million
Q3 2021 Nov 16, 2021	BUY	$7.64 - $12.49 $595,996 - $974,344	78,010 Added 80.02%	175,493 $1.93 Million
Q2 2021 Aug 16, 2021	BUY	$8.68 - $27.49 $40,717 - $128,955	4,691 Added 5.06%	97,483 $846,000
Q1 2021 May 18, 2021	BUY	$12.0 - $27.64 $727,536 - $1.68 Million	60,628 Added 188.5%	92,792 $1.41 Million
Q4 2020 Feb 17, 2021	SELL	$11.05 - $16.62 $127,539 - $191,828	-11,542 Reduced 26.41%	32,164 $375,000
Q2 2020 Aug 17, 2020	BUY	$9.75 - $17.6 $153,835 - $277,692	15,778 Added 56.5%	43,706 $652,000
Q2 2019 Aug 15, 2019	BUY	$3.77 - $8.67 $105,288 - $242,135	27,928 New	27,928 $234,000

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account